2181 Stock Overview
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Mabpharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.47 |
| 52 Week High | HK$0.99 |
| 52 Week Low | HK$0.34 |
| Beta | 0.82 |
| 1 Month Change | -4.04% |
| 3 Month Change | -15.18% |
| 1 Year Change | 35.71% |
| 3 Year Change | -59.75% |
| 5 Year Change | n/a |
| Change since IPO | -60.74% |
Recent News & Updates
Recent updates
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09Shareholder Returns
| 2181 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.0% | -1.9% | 1.4% |
| 1Y | 35.7% | 3.9% | 5.2% |
Return vs Industry: 2181 exceeded the Hong Kong Biotechs industry which returned 3.9% over the past year.
Return vs Market: 2181 exceeded the Hong Kong Market which returned 5.2% over the past year.
Price Volatility
| 2181 volatility | |
|---|---|
| 2181 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 14.1% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 2181 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: 2181's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 411 | Hao Wang | https://www.mabpharm.cn |
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China. The company’s products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Mabpharm Limited Fundamentals Summary
| 2181 fundamental statistics | |
|---|---|
| Market Cap | HK$1.96b |
| Earnings (TTM) | -HK$208.13m |
| Revenue (TTM) | HK$76.27m |
25.7x
P/S Ratio-9.4x
P/E RatioIs 2181 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2181 income statement (TTM) | |
|---|---|
| Revenue | CN¥71.09m |
| Cost of Revenue | CN¥10.52m |
| Gross Profit | CN¥60.57m |
| Other Expenses | CN¥254.58m |
| Earnings | -CN¥194.01m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 85.20% |
| Net Profit Margin | -272.90% |
| Debt/Equity Ratio | 49.8% |
How did 2181 perform over the long term?
See historical performance and comparison